Advanced search
Publication Cover
Expert Review of Vaccines Volume 13, 2014 - Issue 1
Submit an article Journal homepage
190
Views
9
CrossRef citations to date
0
Altmetric
Reviews

Recent progress toward development of vaccines against conception

Rajesh K NazDepartment of Obstetrics and Gynecology, Reproductive Immunology and Molecular Biology Laboratory, School of Medicine, West Virginia University, Morgantown, WV, USACorrespondence[email protected]
Pages 145-154 | Published online: 06 Dec 2013

References

  • Naz RK, Rowan S. Female contraception: present and future perspectives. Curr. Womens Health Rev. 5, 167–175 (2009).
  • Naz RK, Rowan S. Update on male contraception. Curr. Opin. Obstet. Gyn. 21, 265–269 (2009).
  • Heinemann K, Saad F, Wiesemes M, White S, Heinemann L. Attitudes toward male fertility control: results of a multinational survey on four continents. Hum. Reprod. 20, 549–556 (2005).
  • Speidel JJ, Harper CC, Shields WC. The potential of long-lasting reversible contraception to decrease unintended pregnancy. Contraception 78, 197–200 (2008).
  • Henshaw SK. Unintended pregnancy in the United States. Fam. Plann. Perspect. 30, 24–29 (1998).
  • Trussel J. Contraceptive failure in the United States. Contraception 70, 89–96 (2004).
  • Landsteiner K. Zur Kenntris der spezifisch auf blutkörperchen wirkenden sera. Zb. Bakt. 25, 546–549 (1899).
  • Metchnikoff E. Etudes sur la resorption de cellule. Ann. Inst. Pasteur. 13, 737–779 (1899).
  • Baskin MJ. Temporary sterilization by injection of human spermatozoa: a preliminary report. Am. J. Obstet. Gynecol. 24, 892–897 (1932).
  • Edwards RG. Immunological control of fertility in female mice. Nature 203, 50–53 (1964).
  • Talwar GP, Gupta SK, Singh V, Sahal D, Iyer KS, Singh O. Bioeffective monoclonal antibody against the decapeptide gonadotropin releasing hormone: reacting determinant and action on ovulation and estrus suppression. Proc. Natl Acad. Sci. USA 82, 1228–1231 (1984).
  • Ladd A, Prabhu G, Tsong YY, Probst T, Chung W, Thau RB. Active immunization against gonadotropin-releasing hormone combined with androgen supplementation is a promising antifertility vaccine for males. Am. J. Reprod. Immunol. 17, 121–127 (1998).
  • Thompson DL. Immunization against GnRH in male species (comparative aspects). Anim. Reprod. Sci. 60–61, 459–469 (2000).
  • Miller LA, Johns BE, Killian GJ. Immunocontraception of white-tailed deer with GnRH vaccine. Am. J. Reprod. Immunol. 44, 266–274 (2000).
  • Kiyama Z, Adams TE, Hess BW, Riley ML, Murdoch WJ, Moss GE. Gonadal function, sexual behavior, feedlot performance and carcass traits of ram lambs actively immunized against GnRH. J. Anim. Sci. 78, 2237–2243 (2000).
  • Jayashankar R, Chaudhari MK, Singh O, Alam A, Talwar GP. Semisynthetic anti-LHRH vaccine causing atrophy of the prostate. Prostate 14, 3–11 (1989).
  • Ferro VA, Stimson WH. Antigonadotropin releasing hormone vaccines and their potential use in the treatment of responsive cancers. BioDrugs 12, 1–12 (1999).
  • Simms MS, Schofield DP, Jacobs E et al. Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer. Br. J. Cancer 83, 443–446 (2000).
  • Levy JK. Contraceptive vaccines for the humane control of community cat populations. Am. J. Reprod. Immunol. 66, 63–70 (2011).
  • Botha AE, Schulman ML, Berschinger HJ, Guthrie AJ, Annandale CH, Hughes SB. The use of a GnRH vaccine to suppress mare ovarian activity in a large group of mares under field conditions. Wildl. Res. 35, 548–554 (2008).
  • Elhay M, Newbold A, Britton A, Turley P, Dowsett K, Walker J. Suppression of behavioral and physiological oestrus in the mare by vaccination against GnRH. Aust. Vet. J. 85, 39–45 (2007).
  • Killian G, Thain D, Diehl DK, Rhyan J, Miller L. Four-year contraception rates of mares treated with single-injection porcine zona pellucida and GnRH vaccines and intrauterine devices. Wildl. Res. 35, 531–539 (2008).
  • Boedeker NC, Murray S, de Avila DM, Brown JL. Effects of a GnRH vaccine on the estrous cycle of an Asian elephant. Proceedings of the AAZV/AAWV Joint Conference, Tulsa, OK. USA 52–52 (2009).
  • Kirkpatrick JF, Lyda RO, Frank, KM. Contraceptive vaccines for wildlife: a review. Am. J. Reprod. Immunol. 66, 40–50 (2011).
  • Naz RK. Contraceptive vaccines: success, status, and future perspective. Am. J. Reprod. Immunol. 66, 2–4 (2011).
  • Sairam MR, Krishnamurthy H. The role of follicle-stimulating hormone in spermatogenesis: lessons from knockout animals models. Arch. Med. Res. 32, 601–608 (2001).
  • Moudgal NR, Dighe RR. Is FSH-based contraceptive vaccines a feasible proposition for the human male? In: Reproductive Immunology. Gupta SK ( Ed.). Narosa Press, New Dehli, India, 346–357 (1999).
  • Moudgal NR, Murthy GS, Prasanna Kumar KM et al. Responsiveness of human male volunteers to immunization with ovine follicule stimulating hormone vaccine: results of a pilot study. Hum. Reprod. 12, 457–463 (1997).
  • Jeyakumar M, Suresh R, Krishnamurthy HN, Moudgal NR. Changes in testicular function following specific deprivation of LH in the adult male rabbit. J. Endocrinol. 147, 111–120 (1995).
  • Saxena BB, Clavio A, Singh M et al. Modulation of ovarian function in female dogs immunized with bovine luteinizing hormone receptor. Reprod. Domest. Anim. 37, 9–17 (2002).
  • Thau RB, Wilson CB, Sundaram K et al. Long-term immunization against the beta-subunit of ovine luteinizing hormone (oLH beta) has no adverse effects on pituitary function in rhesus monkeys. Am. J. Reprod. Immunol. Microbiol. 15, 92–98 (1987).
  • Yanagimachi R. Mammalian fertilization. In: The Physiology of Reproduction. Knobil E, Neill J ( Eds). Raven Press, NY, USA 189–317 (1994).
  • Wassarman PM. Mammalian fertilization: molecular aspects of gamete adhesion, exocytosis, and fusion. Cell 96, 175–183 (1999).
  • Naz RK, Sacco A, Singh O, Pal R, Talwar GP. Development of contraceptive vaccines for humans using antigens derived from gamete (spermatozoa and zona pellucida) and hormones (human chorionic gonadotrophin): current status. Hum. Reprod. Update. 1, 1–18 (1995).
  • Aitken JR. Immunocontraceptive vaccines for human use. J. Reprod. Immunol. 57, 273–287 (2002).
  • Sacco AG, Subramanian MG, Yurewicz EC, DeMayo FJ, Dukelow WR. Heteroimmunization of squirrel monkeys (Saimiri sciureus) with a purified porcine zona antigen (PPZA): immune response and biological activity of antiserum. Fertil. Steril. 39, 350–358 (1983).
  • Dunbar BS, Lo CL, Powell J, Stevens VC. Use of a synthetic peptide adjuvant for immunization of baboons with denatured and deglycoslyated pig zona pellucida glycoproteins. Fertil. Steril. 52, 311–318 (1989).
  • Keenan JA, Sacco AG, Subramanian MG, Kruger M, Yurewicz EC, Moghissi KS. Endocrine response in rabbits immunized with native versus deglycosylated porcine zona pellucida antigens. Biol. Reprod. 44, 150–156 (1991).
  • Millar SE, Chamow SM, Baur AW, Oliver C, Robey F, Dean J. Vaccination with a synthetic zona pellucida peptide produces long-term contraception in female mice. Science 246, 935–938 (1989).
  • Govind CK, Gupta SK. Failure of female baboons (Papio Anubis) to conceive following immunization with recombinant non-human primate zona pellucida glycoprotein-B expressed in Escherichia coli. Vaccine 18, 2970–2978 (2000).
  • Rhim SH, Millar SE, Robey F et al. Autoimmune disease of the ovary induced by a ZP3 peptide from the mouse zona pellucida. J. Clin. Invest. 89, 28–35 (1992).
  • Tung KSK, Lou Y, Bagavant H. Zona pellucida chimeric peptide vaccine. In: Reproductive Immunology. Gupta SK ( Ed.). Narosa Publishing House, New Delhi, India, 303–308 (1999).
  • Miller LA, Killian GJ. In search of the active PZP epitope in white-tailed deer immunocontraception. Vaccine 20, 2735–3742 (2002).
  • Fayrer-Hosken RA, Grobler D, Van Altena JJ, Bertschinger HJ, Kirkpatrick JF. Immunocontraception of African elephants. Nature 407, 149 (2000).
  • Srivastava N, Santhanam R, Sheela P et al. Evaluation of the immunocontraceptive potential of Escherichia coli-expressed recombinant dog ZP2 and ZP3 in a homologous animal model. Reproduction 123, 847–857 (2002).
  • Gupta SK, Srinivasan VA, Suman P et al. Contraceptive vaccines based on the zona pellucida glycoproteins for dogs and other wildlife population management. Am. J. Reprod. Immunol. 66, 51–62 (2011).
  • Naz RK. Antisperm contraceptive vaccines: where we are and where are we going? Am. J. Reprod. Immunol. 66, 5–12 (2011).
  • Immune Infertility. Krause WKH, Naz RK ( Eds). Springer-Verlag, Berlin, Heidelberg, Germany, 1–236 (2009).
  • Naz RK, Zhu X. Recombinant fertilization antigen-1 causes a contraceptive effect in actively immunized mice. Biol. Reprod. 59, 1095–1100 (1998).
  • Naz RK, Chauhan S. Human sperm-specific peptide vaccine that causes long-term reversible contraception. Biol. Reprod. 64, 674–680 (2002).
  • O’Hearn PA, Liang ZG, Bambra CS, Goldberg E. Colinear synthesis of an antigen-specific B-cell epitope with a promiscuous tetanus toxin T-cell epitope: a synthetic peptide immunocontraceptive. Vaccine 15, 1761–1766 (1997).
  • O’Rand MG, Beavers J, Widgren E, Tung K. Inhibition of fertility in female mice by immunization with a B-cell epitope, the synthetic sperm peptide, P10G. J. Reprod. Immunol. 25, 89–102 (1993).
  • Lea JA, van Lierop MJC, Widgren EE et al. A chimeric sperm peptide induced antibodies and strain-specific reversible infertility in mice. Biol. Reprod. 59, 527–536 (1998).
  • Hardy CM, Mobbs JK. Expression of recombinant mouse sperm protein sp56 and assessment of its potential for use as an antigen in an immunocontraceptive vaccine. Mol. Reprod. Dev. 52, 527–536 (1999).
  • Khobarekar BG, Vernekar V, Raghavan V, Kamada M, Maegawa M, Bandivdekar AH. Evaluation of the potential of synthetic peptides of 80 kDa human sperm antigen (HSA) for the development of contraceptive vaccine for male. Vaccine 26, 3711–3718 (2008).
  • O’Rand MG, Widgren EE, Sivashanmugam P et al. Reversible immunocontraception in male monkeys immunized with Eppin. Science 306, 1189 (2004).
  • Naz RK. Immunocontraceptive effect of Izumo and enhancement by combination vaccination. Mol. Reprod. Dev. 75, 336–344 (2008).
  • Tollner TL, Overstreet JW, Branciforte D, Primakoff PD. Immunization of female cynomolgus macaques with a synthetic epitope of sperm-specific lactate dehydrogenase results in high antibody titers but does not reduce fertility. Mol. Reprod. Dev. 62, 257–264 (2002).
  • Naz RK. Vaccine for contraception targeting sperm. Immunol. Rev. 171, 193–202 (1999).
  • Naz RK. Female genital tract immunity: distinct immunological challenges for vaccine development. J. Reprod. Immunol. 93, 1–8 (2012).
  • Liu MA. DNA vaccines: a review. J. Intern. Med. 253, 402–410 (2003).
  • Naz RK, Chauhan SC, Rose LP. Expression of alpha and gamma interferon receptors in the sperm cell. Mol. Reprod. Dev. 56, 189–197 (2000).
  • Naz RK. Effect of sperm DNA vaccine on fertility of female mice. Mol. Reprod. Dev. 73, 918–928 (2006).
  • Naz RK. Effect of fertilization antigen (FA-1) DNA vaccine on fertility of female mice. Mol. Reprod. Dev. 73, 1473–1479 (2006).
  • Lemons AR, Naz RK. Contraceptive vaccines targeting factors involved in establishment of pregnancy. Am. J. Reprod. Immunol. 66, 13–25 (2011).
  • Robb L, Dimitriadis E, Li R, Salamonsen LA. Leukemia inhibitory factor and interleukin-11: cytokines with key roles in implantation. J. Reprod. Immunol. 57, 129–141 (2002).
  • Trouillas M, Saucourt C, Guillotin B et al. The LIF cytokine: towards adulthood. Euro. Cytokin. Netw. 20, 51–62 (2009).
  • Dimitriadis E, Menkhorst E. New generation contraceptives: interleukin 11 family cytokines as non-steroidal contraceptive targets. J. Reprod. Immunol. 88, 233–239 (2011).
  • Fedorcsak P, Storeng R. Effects of leptin and leukemia inhibitory factor on preimplantation development and STAT3 signaling of mouse embryos in vitro. Biol. Reprod. 69, 1531–1538 (2003).
  • Bhatt H, Brunet LJ, Stewart CL. Uterine expression of leukemia inhibitory factor coincides with the onset of blastocyst implantation. Proc. Natl Acad. Sci. USA 88, 11408–11412 (1991).
  • Stewart CL, Kaspar P, Brunet LJ et al. Blastocyst implantation depends on maternal expression of leukemia inhibitory factor. Nature 359, 76–79 (1992).
  • White CA, Zhang JG, Salamonsen LA et al. Blocking LIF action in the uterus by using a PEGylated antagonist prevents implantation: a nonhormonal contraceptive strategy. Proc. Natl Acad. Sci. USA 104, 19357–19362 (2007).
  • Terakawa J, Wakitani S, Sugiyama M et al. Embryo implantation is blocked by intraperitoneal injection with anti-LIF antibody in mice. J. Reprod. Dev. 57, 700–707 (2011).
  • Sengupta J, Lalitkumar PG, Najwa AR, Ghosh D. Monoclonal anti-leukemia inhibitory factor antibody inhibits blastocyst implantation in the rhesus monkey. Contraception 74, 419–425 (2006).
  • Catalano RD, Johnson MH, Campbell EA, Charnock-Jones DS, Smith SK, Sharkey AM. Inhibition of Stat3 activation in the endometrium prevents implantation: a nonsteroidal approach to contraception. Proc. Natl Acad. Sci. USA 102, 8585–8590 (2005).
  • Nakamura H, Kimura T, Koyama S et al. Mouse model of human infertility: transient and local inhibition of endometrial STAT-3 activation results in implantation failure. FEBS Lett. 580, 2717–2722 (2006).
  • Mohamet L, Heath JK, Kimber SJ. Determining the LIF-sensitive period for implantation using a LIF-receptor antagonist. Reproduction. 138, 827–836 (2009).
  • Cullinan EB, Abbondanso SJ, Anderson PS, Pollard JW, Lessey BA, Steward CL. Leukemia inhibitory factor (LIF) and LIF receptor expression in human endometrium suggest a potential autocrine/paracrine function in regulating embryo implantation. Proc. Natl Acad. Sci. USA 93, 3115–3210 (1996).
  • Vogiagis D, Marsh MM, Fry RC, Salamonsen LA. Leukemia inhibitory factor in human endometrium throughout the menstrual cycle. J. Endocrinol. 148, 95–102 (1996).
  • Yang Y, Geraghty DE, Hunt JS. Cytokine regulation of HLA-G expression in human trophoblast cell lines. J. Reprod. Immunol. 29, 179–195 (1995).
  • Charnock-Jones DS, Sharkey AM, Fenwick P, Smith SK. Leukemia inhibitory factor mRNA concentration peaks in human endometrium at the time of implantation and the blastocyst contains mRNA for the receptor at this time. J. Reprod. Fertil. 101, 421–426 (1994).
  • Arici A, Engin O, Attar E, Olive DL. Modulation of leukemia inhibitory factor gene expression and protein biosynthesis in human endometrium. J. Clin. Endocrinol. Metab. 80, 1908–1915 (1995).
  • Nachtigall MJ, Kliman HJ, Feinberg RF, Olive DL, Engin O, Arici A. The effect of leukemia inhibitory factor (LIF) on trophoblast differentiation: a potential role in human implantation. J. Clin. Endocrinol. Metab. 81, 801–805 (1996).
  • Sharkey AM, Dellow K, Blayney M, Macnamee M, Charnock-Jones S, Smith SK. Stage-specific expression of cytokine and receptor messenger ribonucleic acids in human preimplantation embryos. Biol. Reprod. 53, 974–981 (1995).
  • Giess R, Tanasescu I, Steck T, Sendtner M. Leukemia inhibitory factor gene mutations in infertile women. Mol. Hum. Reprod. 5, 581–586 (1999).
  • Wu MY, Chen HF, Cheu SU, Chao KH, Yang YS, Ho HN. Increase in the production of interleukin-10 early after implantation is related to the success of pregnancy. Am. J. Reprod. Immunol. 46, 386–392 (2001).
  • Ledee-Bataille N, Lapree-Delage G, Taupin JL, Dubanchet S, Frydman R, Chaouat G. Concentration of leukemia inhibitory factor (LIF) in uterine flushing fluid is highly predictive of embryo implantation. Hum. Reprod. 14, 213–218 (2002).
  • Salamonsen LA, Nie G, Hannan NJ, Dimitriadis E. Society for Reproductive Biology Founders’ Lecture 2009. Preparing fertile soil: the importane of endometrial receptivity. Reprod. Fertil. Dev. 21, 923–934 (2009).
  • Chaouat G, Menu E, Delage G et al. Immuno-endocrine interactions in early pregnancy. Hum. Reprod. 10, 55–59 (1995).
  • Delage G, Moreau JF, Taupin JL et al. In-vitro endometrial secretion of human interleukin for DA cells/leukaemia inhibitory factor by explant cultures from fertile and infertile women. Human Reprod. 10, 2483–2488 (1995).
  • Novotny Z, Krizan J, Sima R et al. Leukaemia inhibitory factor (LIF) gene mutations in women diagnosed with unexplained fertility and endometriosis have a negative impact on the IVF outcome. A pilot study. Folia. Biol. (Praha) 55, 92–97 (2009).
  • Kang HJ, Feng Z, Sun Y et al. Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc. Natl Acad. Sci. USA 106, 9761–9766 (2009).
  • Lemons AR, Naz RK. Birth control vaccine targeting leukemia inhibitory factor. Mol. Reprod. Dev. 79, 97–105 (2012).
  • Hearn JP, Gidley-Baird AA, Hodges JK, Summers PM, Webley GE. Embryonic signals during the pre-implantation period in primates. J. Reprod. Fertil. Suppl. 36, 49–58 (1988).
  • Contraception ( entire February issue of 15 papers). Elsevier, 13, 129–268 (1976).
  • Nash H, Talwar GP, Segal S et al. Observation on the antigenicity and clinical effects of a candidate antipregnancy vaccine: beta-subunit of human chorionic gonadotropin linked to tetanus toxid. Fertil. Steril. 34, 328–335 (1980).
  • Thau RB, Wilson CB, Sundaram K et al. Long term immunization against the beta-subunit of ovine luteinizing hormone (oLH-beta) has no adverse effects on pituitary function in rhesus monkeys. Am. J. Reprod. Immunol. Microbiol. 15, 92–98 (1987).
  • Thau RB. Active immunization of rhesus monkeys against the beta-subunit of ovine luteinizing hormone: evaluation of safety and effectiveness of anti-gonadotropin vaccine. In: Contraception Research for Today and the Nineties. Talwar GP ( Ed.). Springer Verlag, NY, USA 217–230 (1988).
  • Talwar GP, Singh O, Pal R et al. A vaccine that prevents pregnancy in women. Proc. Natl Acad. Sci. USA 91, 8532–8536 (1994).
  • Talwar GP. Making of a vaccine preventing pregnancy without impairment of ovulation and derangement of menstrual regularity and bleeding profiles. Contraception 87, 280–287 (2013).
  • Talwar GP, Vyas HK, Purswani S, Gupta JC. Gonadotropin-releasing hormone/human chorionic gonadotropin beta based recombinant antibodies and vaccines. J. Reprod. Immunol. 83, 158–163 (2009).
  • Talwar GP. A unique vaccine for control of fertility and therapy of advanced-stage terminal cancers ectopically expressing human chorionic gonadotropin. Ann. N. Y. Acad. Sci. 1283, 50–56 (2013).
  • Purswani S, Talwar GP, Vohra R et al. Mycobacterium indicus pranii is a potent immunomodulator for a recombinant vaccine against human chorionic gonadotropin. J. Reprod. Immunol. 91, 24–30 (2011).
  • Purswani S, Talwar GP. Development of a highly immunogenic recombinant candidate vaccine against human chorionic gonadotropin. Vaccine 29, 2341–2348 (2011).
  • Talwar GP, Gupta JC, Shankar NV. Immunological approaches against human chorionic gonadotropin for control of fertility and therapy advanced-stage cancers expressing hCG/subunits. Am. J. Reprod. Immunol. 66, 26–39 (2011).
  • Chua BY, Al Kobaisi M, Zeng W, Mainwaring D, Jackson DC. Chitosan microparticles and nanoparticles as biocompatible delivery methods for peptide and protein-based immunocontraceptive vaccines. Mol. Pharm. 9, 81–90 (2012).
  • Ulery BD, Kumar D, Ramer-Tait AE, Metzger DW, Wannemuehler MJ, Narasimhan B. Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS ONE 6, e17642–e17649 (2011).
  • Petersen LK, Phanse Y, Ramer-Tait AE, Wannemuehler MJ, Narasimhan B. Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen. Mol. Pharm. 9, 874–882 (2012).
  • Curtiss R, Xin W, Li Y et al. New technologies in using recombinant attenuated Salmonella vaccine vectors. Critic. Rev. Immunol. 30, 255–270 (2010).
  • Curtiss R. The impact of vaccines and vaccinations: challenges and opportunities for modelers. Math. Biosci. Eng. 8, 77–93 (2011).
  • Hollinger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Natl Biotechnol. 23, 1126–1136 (2005).
  • Samuel AS, Naz RK. Isolation of human single chain variable fragment antibodies against specific sperm antigens for immunocontraceptive development. Hum. Reprod. 23, 1324–1337 (2008).
  • Naz RK. Development of genetically engineered human sperm immunocontraceptives. J. Reprod. Immunol. 83, 145–150 (2009).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.